Skip to main content
. 2020 May 20;50(3):632–639. doi: 10.1007/s11239-020-02143-2

Fig. 2.

Fig. 2

a Percentage of rivaroxaban plasma concentrations below and above the treatment-relevant thresholds of 30 and 50 ng/mL found at different level of CoaguChek®-international normalized ratio (CC-INR), and b receiver operating characteristics curve found for CC-INR when testing for detection of samples containing rivaroxaban plasma concentrations ≤ 30 and ≤ 50 ng/mL